Gomez Honored by Avon Foundation
Dr. Gomez referred to the program as "a flexible granting mechanism approach with fast decisions and an invaluable partnership with tremendous insight into the challenges of breast cancer research."
Niederhuber Addresses Cancer Center Directors
Barbara Duffy Stewart, AACI executive director, commented, "We are fortunate to have Dr. Niederhuber address our membership in his new role as NCI Director. We look forward to continuing our relationship with him and facilitating communication between NCI and the cancer centers in these fiscally challenging times."
SPN Monograph Available
This monograph highlights the activities and accomplishments of the Special Populations Networks program (SPN), a 5-year, nationwide NCI-funded program to reduce cancer health disparities in minority and medically underserved populations. The monograph is available online at http://www3.interscience.wiley.com/cgi-bin/jissue/113386997.
During the early 1950s, Dr. Venditti's laboratory work was instrumental in developing a number of anticancer drugs. He was considered one of the world's leading experts on drug interactions and for many years was a member of NCI's Acute Leukemia Task Force. From 1966 to 1986, he directed the NCI anticancer drug screening program, a worldwide network of research and development projects for the discovery of improved chemotherapy. In 1983, he established National Cooperative Drug Discovery Groups, and directed the program until his retirement from government service in 1987.
Dr. Venditti received his undergraduate degree from the University of Maryland, and his doctorate in pharmacology from George Washington University. Dr. Venditti was an author on more than 160 scientific publications and several book chapters, and had been scientific editor of Cancer Chemotherapy Reports.
Survivors include his wife Nancy, three children, and three grandchildren.